Alissa Thomas
Associate Professor, Neurological Sciences
Director, Neurology Residency Program
Associate Designated Institutional Official, Graduate Medical Education
PRONOUNS she/her
- M.D., Warren Alpert Medical School of Brown University, Providence, RI
- Candidate for MD, Dartmouth Medical School, Hanover, NH
- A.B., Bowdoin College, Brunswick, ME
- Residency, Neurology, Dartmouth Hitchcock Medical Center, Lebanon, NH
- Fellowship, Neuro-Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
Department of Neurological Sciences
Division of Hematology and Oncology
UVM Cancer Center
Areas of expertise
primary brain tumors, metastatic brain tumors, glioblastoma, neuro-oncology, resident education, clinical trials.
BIO
Alissa Thomas is an Associate Professor of Neurological Sciences at the University of Vermont Larner College of Medicine and the Division Chief of Neuro-oncology at the University of Vermont Medical Center. Her clinical practice is focused on neuro-oncologic care for patients with primary and metastatic brain tumors. Dr. Thomas is a clinical trialist at the University of Vermont Cancer Center. She brings in trials of novel therapeutics for patients with tumors the nervous system, and she has a special research interest in access to care for patients from rural areas. She serves at the chair of the protocol review and monitoring committee for the UVM Cancer Center. Dr Thomas is the Neurology Residency Program Director and the Associate Designated Institutional Official for Graduate Medical Education at the University of Vermont Medical Center. She is a Distinguished Educator at the University of Vermont Larner College of Medicine Teaching Academy.
Publications
Awards and Achievements
- Distinguished Educator, University of Vermont Larner College of Medicine, 2025
- Fellow, American Academy of Neurology, 2023
- Graduate, American Academy of Neurology Transforming Leaders Program, 2024
- Vice Chair, American Academy of Neurology, Neuro-oncology section, 2025-2027
- Co-Chair, Society for Neuro-Oncology Career Development Committee, 2026-2028
- Robert Hamil Neurology Resident Teaching Award, UVM Department of Neurological Sciences, 2018
- Juckett Scholar, University of Vermont Cancer Center, 2022
- University of Vermont Medical Group Junior Researcher of the Year, 2017
Bio
Alissa Thomas is an Associate Professor of Neurological Sciences at the University of Vermont Larner College of Medicine and the Division Chief of Neuro-oncology at the University of Vermont Medical Center. Her clinical practice is focused on neuro-oncologic care for patients with primary and metastatic brain tumors. Dr. Thomas is a clinical trialist at the University of Vermont Cancer Center. She brings in trials of novel therapeutics for patients with tumors the nervous system, and she has a special research interest in access to care for patients from rural areas. She serves at the chair of the protocol review and monitoring committee for the UVM Cancer Center. Dr Thomas is the Neurology Residency Program Director and the Associate Designated Institutional Official for Graduate Medical Education at the University of Vermont Medical Center. She is a Distinguished Educator at the University of Vermont Larner College of Medicine Teaching Academy.
Publications
Awards and Achievements
- Distinguished Educator, University of Vermont Larner College of Medicine, 2025
- Fellow, American Academy of Neurology, 2023
- Graduate, American Academy of Neurology Transforming Leaders Program, 2024
- Vice Chair, American Academy of Neurology, Neuro-oncology section, 2025-2027
- Co-Chair, Society for Neuro-Oncology Career Development Committee, 2026-2028
- Robert Hamil Neurology Resident Teaching Award, UVM Department of Neurological Sciences, 2018
- Juckett Scholar, University of Vermont Cancer Center, 2022
- University of Vermont Medical Group Junior Researcher of the Year, 2017
Select Publications
- Thomas AA, Pollard R, Ulep R, Mohile N. “Implementing anti-racism education in residency training: a multi-center pilot study.” Neurology Education, 2026, Mar
- Thomas AA, Wright H, Chan K , Ross H, Prasad P, Goodwin A, Holmes CE. Safety of apixaban for venous thromboembolism primary prophylaxis in patients with newly diagnosed malignant glioma.” Journal of Thrombosis and Thrombolysis. 2022 Feb,; 53(2): 479-484.
- Sutherland I, Ulano A, Thomas AA. “Pseudoprogression on MRI following radiation therapy in patients with low grade IDH mutant glioma” Neuro-Oncology Practice 22Feb2025.
- Sarriera Valentin G, D’Agostino E, Callas P, Thomas AA. “Retrospective analysis of clinical presentation and treatment of patients with glioblastoma in rural and urban counties.” BMC Health Services Research 2025, 25: 1052
- Thomas AA, Abrey LE, Terziev R, Raizer J, Martinez NL, Forsyth P, Paleologos N, Matasar M, Sauter CS, Moskowtiz C, Nimer SD, DeAngelis LM, Kaley T, Grimm S, Louis DN, Cairncross JG, Panageas KS, Briggs S, Faivre G, Mohile NA, Mehta J, Jonsson P, Chakravarty D, Gao J, Schultz N, Brennan CW, Huse JT, Omuro A. “Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-Oncology.2017; 19(10): 1380-1390.